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Introduction
The Blood and Clot Thrombectomy Registry and 
Collaboration (BACTRAC) (clinicaltrials.gov NCT031536 
83), a continuously enrolling tissue bank at the University of 
Kentucky, collects arterial blood distal and proximal to the 
thrombus from stroke patients undergoing thrombectomy 
[1]. Plasma proteins from these samples have been 
Abstract
Introduction: Uromodulin (UMOD) is a glycoprotein expressed by the epithelial cells of the thick ascending limb of Henle’s loop 
in the kidney. Research has shown that increased uromodulin expression may be associated with lower risk of cardiovascular disease 
in adults. Utilizing the Blood and Clot Thrombectomy Registry and Collaboration (BACTRAC) (clinicaltrials.gov NCT03153683), a 
continuously enrolling tissue bank, we aimed to examine the associations between serum uromodulin, age, and high BMI (BMI>25) 
and its relationship to stroke in patients. 
Methods: Arterial blood distal and proximal to the thrombus was collected during a thrombectomy procedure using the BACTRAC 
protocol and sent to Olink (Boston, MA) to determine proteomic expression via proximity extension assay. Uromodulin expression 
was recorded and analyzed using two tailed T-tests and linear regressions.
Results: The relationship between systemic and intracranial uromodulin, age, high BMI and hypertension were assessed. Systemic 
and intracranial uromodulin decreased with age (p<0.0001 and r²=0.343, p=0.0416 and r²=0.102) respectively. Systemic uromodulin 
expression increased with BMI>25 (p=0.014). Presence of hypertension decreased uromodulin’s expression systemically (p=0.018) 
and intracranially (p=0.007). 
Conclusions: Uromodulin was increased significantly in overweight patients, decreased significantly in older patients, and decreased 
in patients with hypertension. The increase in uromodulin in people with high BMI could be a protective reaction of the kidney to 
worsening conditions that make ischemic stroke more likely, with a goal of delaying dangerous outcomes. The decreased expression 
of uromodulin in older adults could be associated with the decline of general kidney function that accompanies aging. Hypertension 
can contribute to an AKI by decreasing perfusion to the kidney, therefore decreasing kidney function and uromodulin production. 
Further analyses are needed to understand the role of uromodulin following ischemic stroke.
Keywords: Ischemic Stroke, Uromodulin protein, High Body Mass Index (BMI), Age, Blood and Clot Thrombectomy Registry 
and Collaboration (BACTRAC)
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isolated and analyzed to create a proteomic database [2]. 
This database can be utilized to determine proteomic 
associations in stroke by linking the protein’s expression 
to patient’s demographics and clinical outcomes. This 
biobank has an enormous amount of information and 
numerous uses that are not limited to stroke pathology. 
This biobank can be used for broad purposes such as 
protein expression and its use as clinical biomarkers. For 
this study, uromodulin (UMOD), was chosen to determine 
its association with patient demographics and clinical 
outcomes to highlight the multi-faceted uses of the biobank. 
Uromodulin, also known as Tamm-Horsfall protein, is 
a glycoprotein that is expressed by the epithelial cells of 
the thick ascending limb of Henle’s loop in the kidney. 
It is excreted in the urine and is the main component of 
hyaline urinary casts. Uromodulin is the most abundant 
urinary protein in healthy individuals, and has important 
roles in ion transport, water and electrolyte balance, and 
prevention of urinary tract infections [3]. Reduced levels 
of urinary uromodulin have been associated with acute 
tubular necrosis, diabetic nephropathy, active lupus 
nephritis, mortality and cardiovascular disease [4,5]. Most 
studies of uromodulin have focused on utilizing urinary 
uromodulin and less is known about serum uromodulin. 
Recently, there has been a revival of interest in studies 
with serum uromodulin as more assays have become 
available. Research has shown that increased uromodulin 
expression may be associated with lower risk of 
cardiovascular disease in adults [5]. One study showed that 
higher serum uromodulin concentration was associated 
with a beneficial metabolic profile, lower prevalence rates 
of arterial hypertension, diabetes mellitus, heart failure 
and a lower risk for 10-year mortality [3]. Another study 
demonstrated an inverse association of serum uromodulin 
with arterial hypertension in a large population-based study 
[6]. Utilizing the proteomic data base from BACTRAC, we 
aimed to analyze uromodulin in the setting of large vessel 
occlusion stroke to understand the relationship between 
its intravascular levels and specific elements of stroke 
such as age, increased BMI (BMI>25), and other common 
comorbidities tied to increased stroke. 
Materials & Methods
This study evaluated 42 adult subjects (>18yrs), of 
which 31 were female (57%), average age of 66.8 ± 16.7, 
average BMI of 25.7 ± 6.7, and 31 (74%) of them had self-
reported documented hypertension. During a mechanical 
thrombectomy, arterial blood distal and proximal to the 
thrombus was collected using the previously described 
BACTRAC protocol [1] and sent to Olink (Boston, MA) to 
determine proteomic expression via proximity extension 
assay. Uromodulin expression was recorded and analyzed 
using Welch’s two tailed T-tests and linear regressions. 
P-value of 0.05 was considered significant. Systemic 
uromodulin was the uromodulin expression found in 
arterial blood proximal to the thrombus. Intracranial 
uromodulin was the uromodulin expression found in 
arterial blood distal to the thrombus.
Results
The relationship between systemic and intracranial 
uromodulin, high BMI, age and hypertension were found 
significant. Figures 1a and 1b show that systemic and 






Figure 1a: Uromodulin protein plasma expression is 













Figure 1b: Uromodulin protein plasma expression is 
decreased in intracranial arterial blood with age (p=0.0416 
and r²=0.102).
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and r²=0.343, p=0.0416 and r²=0.102). Figure 2a shows 
systemic uromodulin expression increased with BMI>25 
(p=0.0139) while figure 2b shows no significant change 
in intracranial expression. The relationship between 
systemic and intracranial uromodulin expression and the 
presence of acute ischemic stroke were assessed. Figures 
3a and 3b show that systemic and intracranial uromodulin 




In our study, uromodulin was found to be increased 
significantly in overweight patients (BMI>25). In 2017-
2018, the prevalence of obesity in adults was 42.4% [7], 
highlighting the prevalence of a major risk factor for 
stroke. Research has shown that increased uromodulin 
expression levels has been associated with lower 











Figure 2a: Uromodulin protein plasma expression is 








Figure 2b: Uromodulin protein plasma expression showed 
no significant change in intracranial arterial blood based on 









Figure 3a: Uromodulin protein plasma expression is 




















Figure 3b: Uromodulin protein plasma expression is 
decreased in intracranial arterial blood in patients with 
hypertension (p=0.0066).
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increase in uromodulin in people with high BMI could be 
a protective reaction of the kidney to worsening conditions 
(i.e. overweight and obesity) that make ischemic stroke 
more likely. Studies have indicated that the prevalence of 
hyperfiltration, a precursor to chronic kidney disease, is 
higher among individuals with obesity and this could serve 
as an alternative explanation to our findings of increased 
UMOD expression in those that have a high BMI [8].
Uromodulin was found to be decreased significantly 
in older patients. Aging is one of the most powerful 
non-modifiable risk factors for stroke and the incident 
for stroke doubles every 10 years after age 55 [9]. The 
decreased expression of uromodulin in older adults 
could be associated with the decline of general kidney 
function that accompanies aging. Uromodulin is produced 
exclusively in the kidney and as kidneys age, production 
of uromodulin can decrease as well. Essentially as 
individuals’ age, so do their kidneys. Following a stroke, 
variations in blood pressure and salt wasting, as well as 
treatments and explorations, can all have the possibility 
to contribute to the development of an acute kidney injury 
(AKI) [10]. An AKI can decrease kidney function which can 
include a decrease in uromodulin production, explaining 
the decreased levels of uromodulin expression in those 
that experienced a stroke. 
Uromodulin was found to be decreased in patients with 
hypertension compared to patients without hypertension 
which is a similar finding to a study done in 2020 
demonstrating an inverse relationship with serum 
uromodulin and arterial hypertension [6]. Hypertension 
is prevalent in acute kidney injuries and maintaining 
an ideal blood pressure is important in order to prevent 
an AKI [11]. Hypertension can contribute to an AKI by 
decreasing perfusion to the kidney, therefore decreasing 
kidney function and uromodulin production. Further 
analyses of clinical data are needed to understand the role 
of uromodulin after ischemic stroke.
Conclusion
Utilizing the proteomic data base from BACTRAC, 
we aimed to analyze uromodulin in the setting of large 
vessel occlusion stroke to understand the relationship 
between its intravascular levels and specific elements of 
stroke such as age, high BMI (BMI>25), and other co-
morbidities. In our study, uromodulin was found to be 
increased significantly in overweight patients, decreased 
significantly in older patients and decreased in those 
patients with hypertension. This exercise depicts the 
utility of the BACTRAC proteomic database in which 184 
proteins have been analyzed in intracranial and systemic 
blood from patients undergoing thrombectomy. Any one 
of these 184 proteins can be selected, and its expression 
can be associated with clinical outcomes and patient 
demographics. These results not only elucidate a protein’s 
role in stroke but also its demographic expression. The 
limitations to this study include the relatively small 
sample size of the population and restricted diversity of 
the patient population. In the future, other institutions 
will be collecting and analyzing these blood samples to 
provide greater diversity and sample size which will give 
insight into plasma protein function during stroke and 
their relationship to patient demographics.
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